血管内治疗后随访梗死体积与90天结局不一致性的评估
本研究为ESCAPE-NA1试验的事后分析,纳入1091例接受EVT且有大血管闭塞的缺血性卒中患者,比较随访梗死体积(FIV)与90天mRS评分不一致组与非不一致组在治疗前、治疗相关及治疗后因素上的差异。287例FIV≤7 mL患者中42例(14.6%)mRS≥3,275例FIV≥92 mL患者中65例(23.6%)mRS≤2。预设模型与逐步回归模型AUC相似,SAEs(新发梗死、复发卒中、肺炎、心衰)与低FIV高mRS相关,无SAEs(尤其卒中进展、症状性颅内出血、肺炎)与高FIV低mRS相关。作者认为除预防并发症外,优化血压、血糖和血红蛋白可能是可干预因素,值得进一步研究。
要点
- FIV≤7 mL患者中14.6%(42/287)90天mRS≥3,FIV≥92 mL患者中23.6%(65/275)mRS≤2,提示体积与结局存在不一致。
- SAEs(新发梗死、复发卒中、肺炎、充血性心力衰竭)与低FIV但高mRS评分相关,预设模型AUC 0.92(95%CI 0.89-0.95)与逐步模型0.93(95%CI 0.90-0.95)相似(P=0.42)。
- 无SAEs(尤其卒中进展、症状性颅内出血、肺炎)与高FIV但低mRS评分相关,预设模型AUC 0.80(95%CI 0.74-0.87)与逐步模型0.79(95%CI 0.72-0.86)相似(P=0.92)。
- 年轻年龄与高FIV低mRS相关,逐步模型另识别无糖尿病和较高基线血红蛋白为治疗前因素(AUC 0.76 vs 0.77,P=0.82)。
- 逐步模型识别24小时血红蛋白、血糖和舒张压为与不一致病例相关的治疗后因素,作者认为优化这些指标值得进一步研究。
适用人群与场景
- 参与ESCAPE-NA1试验、接受血管内治疗、有90天mRS评分和24-48小时随访脑实质影像的缺血性卒中患者。
诊断标准与关键阈值
- 小FIV定义为随访梗死体积≤第25百分位数(≤7 mL),大FIV定义为≥第75百分位数(≥92 mL)。
- discrepant病例定义为小FIV但90天mRS≥3,或大FIV但90天mRS≤2。
研究设计与关键结果
- 研究类型为ESCAPE-NA1随机对照试验的事后队列分析,纳入1091例患者,中位年龄70.8岁(IQR 60.8-79.8),女性549例(49.7%),中位FIV 24.9 mL(IQR 6.6-92.2)。
- 287例FIV≤7 mL患者中42例(14.6%)mRS≥3;275例FIV≥92 mL患者中65例(23.6%)mRS≤2。
- 预设治疗前因素模型与逐步回归模型识别低FIV高mRS的AUC分别为0.92(95%CI 0.89-0.95)和0.93(95%CI 0.90-0.95),P=0.42。
- SAEs(新发梗死、复发卒中、肺炎、充血性心力衰竭)与低FIV高mRS相关;逐步模型另识别24小时血红蛋白为治疗相关/治疗后因素,AUC 0.92(95%CI 0.90-0.95) vs 0.94(95%CI 0.91-0.96),P=0.14。
- 年轻年龄与高FIV低mRS相关;逐步模型另识别无糖尿病和较高基线血红蛋白,AUC 0.76(95%CI 0.70-0.82) vs 0.77(95%CI 0.71-0.83),P=0.82。
- 无SAEs(尤其卒中进展、症状性颅内出血、肺炎)与高FIV低mRS相关;逐步模型另识别24小时血红蛋白、血糖和舒张压,AUC 0.80(95%CI 0.74-0.87) vs 0.79(95%CI 0.72-0.86),P=0.92。
证据类型、等级与局限
- 证据类型为随机对照试验的事后队列分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,除预防新发梗死、复发卒中、肺炎、心衰等并发症外,优化血压、血糖和血红蛋白水平可能是可干预因素,值得进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Some patients have poor outcomes despite small infarcts after endovascular therapy (EVT), while others with large infarcts do well. Understanding why these discrepancies occur may help to optimize EVT outcomes.
OBJECTIVE: To validate exploratory findings from the Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion with Emphasis on Minimizing CT to Recanalization Times (ESCAPE) trial regarding pretreatment, treatment-related, and posttreatment factors associated with discrepancies between follow-up infarct volume (FIV) and 90-day functional outcome.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study is a post hoc analysis of the Safety and Efficacy of Nerinetide in Subjects Undergoing Endovascular Thrombectomy for Stroke (ESCAPE-NA1) trial, a double-blind, randomized, placebo-controlled, international, multicenter trial conducted from March 2017 to August 2019. Patients who participated in ESCAPE-NA1 and had available 90-day modified Rankin Scale (mRS) scores and 24-hour to 48-hour posttreatment follow-up parenchymal imaging were included.
EXPOSURES: Small FIV (volume ≤25th percentile) and large FIV (volume ≥75th percentile) on 24-hour computed tomography/magnetic resonance imaging. Baseline factors, outcomes, treatments, and poststroke serious adverse events (SAEs) were compared between discrepant cases (ie, patients with 90-day mRS score ≥3 despite small FIV or those with mRS scores ≤2 despite large FIV) and nondiscrepant cases.
MAIN OUTCOMES AND MEASURES: Area under the curve (AUC) and goodness of fit of prespecified logistic models, including pretreatment (eg, age, cancer, vascular risk factors) and treatment-related and posttreatment (eg, SAEs) factors, were compared with stepwise regression-derived models for ability to identify small FIV with higher mRS score and large FIV with lower mRS score.
RESULTS: Among 1091 patients (median [IQR] age, 70.8 [60.8-79.8] years; 549 [49.7%] women; median [IQR] FIV, 24.9 mL [6.6-92.2 mL]), 42 of 287 patients (14.6%) with FIV of 7 mL or less (ie, ≤25th percentile) had an mRS score of at least 3; 65 of 275 patients (23.6%) with FIV of 92 mL or greater (ie, ≥75th percentile) had an mRS score of 2 or less. Prespecified models of pretreatment factors (ie, age, cancer, vascular risk factors) associated with low FIV and higher mRS score performed similarly to models selected by stepwise regression (AUC, 0.92 [95% CI, 0.89-0.95] vs 0.93 [95% CI, 0.90-0.95]; P = .42). SAEs, specifically infarct in new territory, recurrent stroke, pneumonia, and congestive heart failure, were associated with low FIV and higher mRS scores; stepwise models also identified 24-hour hemoglobin as treatment-related/posttreatment factor (AUC, 0.92 [95% CI, 0.90-0.95] vs 0.94 [95% CI, 0.91-0.96]; P = .14). Younger age was associated with high FIV and lower mRS score; stepwise models identified absence of diabetes and higher baseline hemoglobin as additional pretreatment factors (AUC, 0.76 [95% CI, 0.70-0.82] vs 0.77 [95% CI, 0.71-0.83]; P = .82). Absence of SAEs, especially stroke progression, symptomatic intracerebral hemorrhage, and pneumonia, was associated with high FIV and lower mRS score2; stepwise models also identified 24-hour hemoglobin level, glucose, and diastolic blood pressure as posttreatment factors associated with discrepant cases (AUC, 0.80 [95% CI, 0.74-0.87] vs 0.79 [95% CI, 0.72-0.86]; P = .92).
CONCLUSIONS AND RELEVANCE: In this study, discrepancies between functional outcome and post-EVT infarct volume were associated with differences in pretreatment factors, such as age and comorbidities, and posttreatment complications related to index stroke evolution, secondary prevention, and quality of stroke unit care. Besides preventing such complications, optimization of blood pressure, glucose levels, and hemoglobin levels are potentially modifiable factors meriting further study.
参考来源
- Ganesh A, Ospel JM, Menon BK, et al. Assessment of Discrepancies Between Follow-up Infarct Volume and 90-Day Outcomes Among Patients With Ischemic Stroke Who Received Endovascular Therapy. JAMA Netw Open. 2021. PMID: 34739060. doi:10.1001/jamanetworkopen.2021.32376
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。